Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
Polyolefin and composition for pipe systems and sheets
Categorization of design rule errors
Inter-cell power control in the presence of fractional frequency reuse
Concentration measuring apparatus for hydrogen sulfide in gas flow, and method for determining sulfide ion
Aisle barrier
Switching module and switching synchronization system
Timing controller capable of removing surge signal and display apparatus including the same
  Randomly Featured Patents
Using URL reputation data to selectively block cookies
Prepayment data transmission system
Process for the production of mono-olefins
Device for connection of an airbag module to a supporting vehicle component
Lane maintenance machine with mechanical lane dressing application controller
Coupling member of pipe coupling
Device for fastening elongate elements to a structure
Electrophotographic recording apparatus indicating a wear rate for consumable parts
Low backlash compensating coupler
Storage tube and cap